Matlou Gauta Gold, Abrahamse Heidi
Laser Research Centre, Faculty of Health Sciences, University of Johannesburg, Doornfontein 2028, South Africa.
Pharmaceutics. 2021 Oct 23;13(11):1773. doi: 10.3390/pharmaceutics13111773.
Hybrid inorganic-organic core-shell nanoparticles (CSNPs) are an emerging paradigm of nanodrug carriers in the targeted photodynamic therapy (TPDT) of cancer. Typically, metallic cores and organic polymer shells are used due to their submicron sizes and high surface to volume ratio of the metallic nanoparticles (NPs), combined with enhances solubility, stability, and absorption sites of the organic polymer shell. As such, the high loading capacity of therapeutic agents such as cancer specific ligands and photosensitizer (PS) agents is achieved with desired colloidal stability, drug circulation, and subcellular localization of the PS agents at the cancer site. This review highlights the synthesis methods, characterization techniques, and applications of hybrid inorganic-organic CSNPs as loading platforms of therapeutic agents for use in TPDT. In addition, cell death pathways and the mechanisms of action that hybrid inorganic-organic core-shell nanodrug systems follow in TPDT are also reviewed. Nanodrug systems with cancer specific properties are able to localize within the solid tumor through the enhanced permeability effect (EPR) and bind with affinity to receptors on the cancer cell surfaces, thus improving the efficacy of short-lived cytotoxic singlet oxygen. This ability by nanodrug systems together with their mechanism of action during cell death forms the core basis of this review and will be discussed with an overview of successful strategies that have been reported in the literature.
无机-有机杂化核壳纳米粒子(CSNPs)是癌症靶向光动力疗法(TPDT)中一种新兴的纳米药物载体范例。通常,由于金属纳米粒子(NPs)的亚微米尺寸和高表面积与体积比,以及有机聚合物壳增强的溶解性、稳定性和吸收位点,所以使用金属核和有机聚合物壳。因此,诸如癌症特异性配体和光敏剂(PS)等治疗剂能够以所需的胶体稳定性、药物循环以及PS剂在癌症部位的亚细胞定位实现高负载量。本综述重点介绍了无机-有机杂化CSNPs作为用于TPDT的治疗剂负载平台的合成方法、表征技术和应用。此外,还综述了无机-有机杂化核壳纳米药物系统在TPDT中遵循的细胞死亡途径和作用机制。具有癌症特异性性质的纳米药物系统能够通过增强渗透效应(EPR)定位于实体瘤内,并与癌细胞表面的受体亲和结合,从而提高短寿命细胞毒性单线态氧的疗效。纳米药物系统的这种能力及其在细胞死亡过程中的作用机制构成了本综述的核心基础,并将结合文献中报道的成功策略进行讨论。